Skip to main content
ConductScienceScienceDex
NIH funding notice PAR-19-304

Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R33 Clinical Trial Optional)

Closed on July 16, 2022.

Posted
June 25, 2019
Close date
July 16, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $375,324 in first-year total cost, median $375,324.

Most frequent study sections

  1. Aging Systems and Geriatrics Study Section[ASG]1

Most frequent institutions

  1. FUNCTION PROMOTING THERAPIES, LLC1
Competing awards under PAR-19-304 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2020Preclinical Characterization of Novel Formulation for Sustained Testosterone Delivery1R33AG068234-01JASUJA, RAVIFUNCTION PROMOTING THERAPIES, LLC, MA$375,324ASG

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
PAR-19-304: Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R33 Clinical Trial Optional) | ScienceDex | ConductScience